Food, Drug Administration discontinues animal testing
On April 10 the U.S. Food and Drug Administration (FDA) announced they are replacing animal testing in the development of monoclonal antibody therapies and other drugs with more effective, human-relevant methods. Monoclonal antibodies (mAbs) are laboratory-produced proteins that can be used to treat various conditions such as cancer, autoimmune diseases and infections. This 2025 decision builds on the FDA Modernization Act 2.0, which was signed in 2022 and allowed for the use of specific alternatives to animal testing. Continue reading Food, Drug Administration discontinues animal testing
